0000014272-18-000158.txt : 20180726 0000014272-18-000158.hdr.sgml : 20180726 20180726080540 ACCESSION NUMBER: 0000014272-18-000158 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20180726 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180726 DATE AS OF CHANGE: 20180726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 18970246 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 q22018earningsrelease8-k.htm 8-K Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): July 26, 2018
 
 
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
 
 
 
 
 
 
 
 
Delaware
 
1-1136
 
22-0790350
(State or Other
Jurisdiction of
Incorporation)
 
(Commission File
Number)
 
(IRS Employer
Identification
Number)

430 E. 29th Street, 14FL, New York, N.Y. 10016
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 









Item 2.02. Results of Operations and Financial Condition.

On July 26, 2018, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the second quarter of 2018. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.











































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 



 
 
BRISTOL-MYERS SQUIBB COMPANY
 
 
 
 
 
Dated: July 26, 2018
 
By:
 
/s/ Katherine R. Kelly
 
 
 
Name:
 
Katherine R. Kelly
 
 
 
Title:
 
Corporate Secretary

 

                           















































EXHIBIT INDEX
 





 EX-99.1 2 q22018ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 26, 2018 Exhibit


Exhibit 99.1
bmslogoq12018a01.jpg

Bristol-Myers Squibb Reports Second Quarter Financial Results


•
Increases Second Quarter Revenues 11% to $5.7 Billion
•
Posts Second Quarter GAAP EPS of $0.23 and Non-GAAP EPS of $1.01
•
Achieves Significant Regulatory Milestones in Oncology
•
Presents Important New Data on Immuno-Oncology Portfolio at ASCO
•
Updates 2018 GAAP and Non-GAAP EPS Guidance

(NEW YORK, July 26, 2018) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2018, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab), and important regulatory progress in the company’s Immuno-Oncology portfolio.

“We had a very good second quarter where we delivered strong performance for Eliquis and Opdivo, and achieved important regulatory and data milestones supporting our Immuno-Oncology portfolio,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “Looking forward, we are focused on robust commercial execution and the evolution of our diversified pipeline to deliver transformational medicines to the patients we serve.”


 
Second Quarter
$ amounts in millions, except per share amounts
 
 
 
 
 
 
2018
 
2017
 
Change
Total Revenues
$
5,704

 
$
5,144

 
11
 %
GAAP Diluted EPS
0.23

 
0.56

 
(59
)%
Non-GAAP Diluted EPS
1.01

 
0.74

 
36
 %













1



SECOND QUARTER FINANCIAL RESULTS

•
Bristol-Myers Squibb posted second quarter 2018 revenues of $5.7 billion, an increase of 11% compared with the same period a year ago. Revenues increased 9% when adjusted for foreign exchange impact.

•
U.S. revenues increased 13% to $3.2 billion in the quarter compared to the same period a year ago. International revenues increased 9%. When adjusted for foreign exchange impact, international revenues increased 4%.

•
Gross margin as a percentage of revenue increased from 69.5% to 71.5% in the quarter primarily due to an impairment charge for a manufacturing site in the prior period.

•
Marketing, selling and administrative expenses decreased 5% to $1.1 billion in the quarter.

•
Research and development expenses increased 45% to $2.4 billion in the quarter, which includes a $1.1 billion charge resulting from the Nektar collaboration in the second quarter of 2018.

•
The effective tax rate was 26.1% in the quarter, compared to 28.8% in the second quarter last year. The effective tax rate includes a nondeductible equity investment loss in the second quarter of 2018.

•
The company reported net earnings attributable to Bristol-Myers Squibb of $373 million, or $0.23 per share, in the second quarter compared to net earnings of $916 million, or $0.56 per share, for the same period in 2017.

•
The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $1.6 billion, or $1.01 per share, in the second quarter, compared to $1.2 billion, or $0.74 per share, for the same period in 2017. An overview of specified items is provided under the “Use of Non-GAAP Financial Information” section.

•
Cash, cash equivalents and marketable securities were $8.2 billion, with a net cash position of $805 million, as of June 30, 2018.



2



SECOND QUARTER PRODUCT AND PIPELINE UPDATE
Product Sales/Business Highlights
Global revenues for the second quarter of 2018, compared to the second quarter of 2017, were driven by:

•
Eliquis, which grew by $474 million or a 40% increase
•
Opdivo, which grew by $432 million or a 36% increase
•
Orencia, which grew by 9%
•
Sprycel, which grew by 6%
•
Yervoy, which decreased by 2%

Opdivo
Regulatory
•
In July, the company announced the U.S. Food and Drug Administration (FDA) approved Opdivo plus low-dose Yervoy (injections for intravenous use) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.
•
In June, the company announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended expanded approval of the current indications for Opdivo to include the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The CHMP recommendation will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union.
•
In June, the company announced the FDA accepted its supplemental Biologics License Application for Opdivo plus low-dose Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb).
•
In June, the China National Drug Administration approved Opdivo for the treatment of locally advanced or metastatic NSCLC after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations.
•
In May, the EMA validated a type II variation application for the Opdivo plus Yervoy combination for treatment in adult patients with first-line metastatic NSCLC who have TMB ≥10 mut/Mb.

Clinical
•
In June, at the 2018 American Society of Clinical Oncology, the company announced important new data and analysis from four studies evaluating Opdivo as monotherapy and in combination with Yervoy, chemotherapy or NKTR-214:

3



◦
CheckMate -227: Results from a part of the Phase 3 trial evaluating Opdivo plus low-dose Yervoy and Opdivo plus chemotherapy versus chemotherapy in patients with first-line advanced NSCLC with PD-L1 expression <1%, across squamous and non-squamous tumor histologies (Part 1b). (link)
◦
CheckMate -238: Results from the Phase 3 trial evaluating Opdivo versus Yervoy in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection. (link)
◦
CheckMate -214: Patient-reported outcomes from the Phase 3 trial evaluating Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period in intermediate- and poor-risk patients with advanced renal cell carcinoma. (link)
◦
Results from the Phase 1/2 dose-escalation study with Nektar Therapeutics, evaluating the safety, efficacy and biomarker data of NKTR-214 in combination with Opdivo for patients enrolled in the Phase 1 dose-escalation stage of the study and for the first patients consecutively enrolled in select dose expansion cohorts in Phase 2. (link)

Sprycel
Regulatory
•
In July, the company announced the EC has expanded the indication for Sprycel to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, and to include a powder for oral suspension formulation.

Empliciti
Clinical
•
In June, the company announced the Phase 2 study evaluating the addition of Empliciti to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma showed a statistically significant and clinically meaningful improvement in progression free survival for patients treated with EPd compared with pomalidomide and dexamethasone alone. (link)


4



SECOND QUARTER BUSINESS DEVELOPMENT UPDATE

•
In July, the company and Tsinghua University announced a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers. The collaboration brings together the respective scientific expertise and capabilities of both organizations with a focus on validating new targets and generating early drug candidates for clinical development.
•
In April, the company and Nektar Therapeutics completed the agreement for the development and commercialization of NKTR-214 with Opdivo and Opdivo plus Yervoy, originally announced in February 2018.
•
In April, the company and Flatiron Health announced a three-year agreement to curate regulatory-grade real-world data for cancer research and real-world evidence generation.

2018 FINANCIAL GUIDANCE

Bristol-Myers Squibb is decreasing its 2018 GAAP EPS guidance range from $2.70 - $2.80 to $2.68 - $2.78 and increasing its non-GAAP EPS guidance range from $3.35 - $3.45 to $3.55 - $3.65. Both GAAP and non-GAAP guidance assume current exchange rates. Key revised 2018 GAAP and non-GAAP line-item guidance assumptions are:

•
Worldwide revenues increasing in the mid- to high-single digits.

The financial guidance for 2018 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2018 guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.
Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related EPS information, that are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods including restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges in connection with the acquisition or licensing of third party intellectual property rights, divestiture and equity investment gains or losses, upfront payments from out-licensed assets, pension charges, legal and other contractual settlements and debt redemption gains or losses, among other items.

5



Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information is an indication of our baseline performance before items that are considered by us to not be reflective of our ongoing results. In addition, this information is among the primary indicators we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to successfully execute its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.






6



Company and Conference Call Information
    
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

There will be a conference call on July 26, 2018 at 10:30 a.m. EDT during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by calling the U.S. toll free 866-548-4713 or international 323-794-2093, confirmation code: 4235170. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on July 26, 2018 through 1:30 p.m. EDT on August 9, 2018. The replay will also be available through http://investor.bms.com or by calling the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 4235170.

For more information, contact:
Communications: Lisa McCormick Lavery, 609-252-7602, lisa.mccormicklavery@bms.com
Investor Relations: John Elicker, 609-252-4611, john.elicker@bms.com, Tim Power, 609-252-7509, timothy.power@bms.com or Bill Szablewski, 609-252-5894, william.szablewski@bms.com.




7



BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUE
FOR THE THREE MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
 
 
Worldwide Revenues
 
U.S. Revenues
 
 
2018
 
2017
 
%
Change
 
2018
 
2017
 
%
Change
Three Months Ended June 30,
 
 
 
 
 
 
 
 
 
 
 
 
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
1,627

 
$
1,195

 
36
 %
 
$
1,024

 
$
768

 
33
 %
Eliquis
 
1,650

 
1,176

 
40
 %
 
979

 
703

 
39
 %
Orencia
 
711

 
650

 
9
 %
 
501

 
449

 
12
 %
Sprycel
 
535

 
506

 
6
 %
 
310

 
281

 
10
 %
Yervoy
 
315

 
322

 
(2
)%
 
228

 
245

 
(7
)%
Empliciti
 
64

 
55

 
16
 %
 
41

 
37

 
11
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
179

 
273

 
(34
)%
 
9

 
12

 
(25
)%
Sustiva Franchise
 
73

 
188

 
(61
)%
 
8

 
161

 
(95
)%
Reyataz Franchise
 
117

 
188

 
(38
)%
 
54

 
87

 
(38
)%
Hepatitis C Franchise
 
12

 
112

 
(89
)%
 
(2
)
 
30

 
**

Other Brands
 
421

 
479

 
(12
)%
 
78

 
92

 
(15
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
$
5,704

 
$
5,144

 
11
 %
 
$
3,230

 
$
2,865

 
13
 %


8



BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUE
FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
 
 
Worldwide Revenues
 
U.S. Revenues
 
 
2018
 
2017
 
%
Change
 
2018
 
2017
 
%
Change
Six Months Ended June 30,
 
 
 
 
 
 
 
 
 
 
 
 
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
3,138

 
$
2,322

 
35
 %
 
$
1,962

 
$
1,529

 
28
 %
Eliquis
 
3,156

 
2,277

 
39
 %
 
1,864

 
1,402

 
33
 %
Orencia
 
1,304

 
1,185

 
10
 %
 
886

 
811

 
9
 %
Sprycel
 
973

 
969

 
—

 
524

 
528

 
(1
)%
Yervoy
 
564

 
652

 
(13
)%
 
390

 
488

 
(20
)%
Empliciti
 
119

 
108

 
10
 %
 
78

 
73

 
7
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
404

 
555

 
(27
)%
 
19

 
26

 
(27
)%
Sustiva Franchise
 
157

 
372

 
(58
)%
 
18

 
314

 
(94
)%
Reyataz Franchise
 
241

 
381

 
(37
)%
 
105

 
175

 
(40
)%
Hepatitis C Franchise
 
15

 
274

 
(95
)%
 
3

 
72

 
(96
)%
Other Brands
 
826

 
978

 
(16
)%
 
159

 
185

 
(14
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
$
10,897

 
$
10,073

 
8
 %
 
$
6,008

 
$
5,603

 
7
 %


9


BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars and shares in millions except per share data)
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2018
 
2017
 
2018
 
2017
Net product sales
 
$
5,461

 
$
4,770

 
$
10,433

 
$
9,350

Alliance and other revenues
 
243

 
374

 
464

 
723

Total Revenues
 
5,704

 
5,144

 
10,897

 
10,073

 
 
 
 
 
 
 
 
 
Cost of products sold
 
1,625

 
1,569

 
3,209

 
2,834

Marketing, selling and administrative
 
1,131

 
1,187

 
2,111

 
2,272

Research and development
 
2,435

 
1,679

 
3,685

 
2,982

Other income (net)
 
(4
)
 
(586
)
 
(404
)
 
(1,265
)
Total Expenses
 
5,187

 
3,849

 
8,601

 
6,823

 
 
 
 
 
 
 
 
 
Earnings Before Income Taxes
 
517

 
1,295

 
2,296

 
3,250

Provision for Income Taxes
 
135

 
373

 
419

 
802

 
 
 
 
 
 
 
 
 
Net Earnings
 
382

 
922

 
1,877

 
2,448

Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
9

 
6

 
18

 
(42
)
Net Earnings Attributable to BMS
 
$
373

 
$
916

 
$
1,859

 
$
2,490

 
 
 
 
 
 
 
 
 
Average Common Shares Outstanding:
 
 
 
 
 
 
 
 
Basic
 
1,633

 
1,644

 
1,633

 
1,653

Diluted
 
1,636

 
1,650

 
1,638

 
1,660

 
 
 
 
 
 
 
 
 
Earnings per Common Share
 
 
 
 
 
 
 
 
Basic
 
$
0.23

 
$
0.56

 
$
1.14

 
$
1.51

Diluted
 
0.23

 
0.56

 
1.13

 
1.50

 
 
 
 
 
 
 
 
 
Other income (net)
 
 
 
 
 
 
 
 
Interest expense
 
$
45

 
$
52

 
$
91

 
$
97

Investment income
 
(38
)
 
(29
)
 
(74
)
 
(55
)
Loss/(gain) on equity investments
 
356

 
(5
)
 
341

 
(12
)
Provision for restructuring
 
37

 
15

 
57

 
179

Litigation and other settlements
 
(1
)
 
(5
)
 
(1
)
 
(489
)
Equity in net income of affiliates
 
(27
)
 
(20
)
 
(51
)
 
(38
)
Divestiture gains
 
(25
)
 
—

 
(70
)
 
(127
)
Royalties and licensing income
 
(353
)
 
(685
)
 
(720
)
 
(884
)
Transition and other service fees
 
(1
)
 
(13
)
 
(5
)
 
(20
)
Pension and postretirement
 
(19
)
 
(11
)
 
(30
)
 
(10
)
Intangible asset impairment
 
—

 
—

 
64

 
—

Loss on debt redemption
 
—

 
109

 
—

 
109

Other
 
22

 
6

 
(6
)
 
(15
)
Other income (net)
 
$
(4
)
 
$
(586
)
 
$
(404
)
 
$
(1,265
)



10



BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2018
 
2017
 
2018
 
2017
Impairment charges
 
$
—

 
$
127

 
$
10

 
$
127

Accelerated depreciation and other shutdown costs
 
14

 
3

 
17

 
3

Cost of products sold
 
14

 
130

 
27

 
130

 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
—

 
—

 
1

 
—

 
 
 
 
 
 
 
 
 
License and asset acquisition charges
 
1,075

 
393

 
1,135

 
443

IPRD impairments
 
—

 
—

 
—

 
75

Site exit costs and other
 
19

 
96

 
39

 
168

Research and development
 
1,094

 
489

 
1,174

 
686

 
 
 
 
 
 
 
 
 
Loss/(gain) on equity investments
 
356

 
—

 
341

 
—

Provision for restructuring
 
37

 
15

 
57

 
179

Litigation and other settlements
 
—

 
—

 
—

 
(481
)
Divestiture gains
 
(25
)
 
—

 
(68
)
 
(100
)
Royalties and licensing income
 
(25
)
 
(497
)
 
(75
)
 
(497
)
Pension and postretirement
 
37

 
36

 
68

 
69

Intangible asset impairment
 
—

 
—

 
64

 
—

Loss on debt redemption
 
—

 
109

 
—

 
109

Other income (net)
 
380

 
(337
)
 
387

 
(721
)
 
 
 
 
 
 
 
 
 
Increase to pretax income
 
1,488

 
282

 
1,589

 
95

 
 
 
 
 
 
 
 
 
Income taxes on specified items
 
(218
)
 
20

 
(226
)
 
92

Income taxes attributed to U.S. tax reform
 
3

 
—

 
(29
)
 
—

Income taxes
 
(215
)
 
20

 
(255
)
 
92

 
 
 
 
 
 
 
 
 
Increase to net earnings
 
1,273

 
302

 
1,334

 
187

 
 
 
 
 
 
 
 
 
Noncontrolling interest
 
—

 
—

 
—

 
(59
)
 
 
 
 
 
 
 
 
 
Increase to net earnings used for diluted Non-GAAP EPS calculation
 
$
1,273

 
$
302

 
$
1,334

 
$
128




11



BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017
(Unaudited, dollars in millions)

 
Three Months Ended June 30, 2018
 
Six Months Ended June 30, 2018
 
GAAP
 
Specified
Items(a)
 
Non-
GAAP
 
GAAP
 
Specified
Items(a)
 
Non-
GAAP
Gross Profit
$
4,079

 
$
14

 
$
4,093

 
$
7,688

 
$
27

 
$
7,715

Marketing, selling and administrative
1,131

 
—

 
1,131

 
2,111

 
(1
)
 
2,110

Research and development
2,435

 
(1,094
)
 
1,341

 
3,685

 
(1,174
)
 
2,511

Other income (net)
(4
)
 
(380
)
 
(384
)
 
(404
)
 
(387
)
 
(791
)
Earnings Before Income Taxes
517

 
1,488

 
2,005

 
2,296

 
1,589

 
3,885

Provision for Income Taxes
135

 
(215
)
 
350

 
419

 
(255
)
 
674

Noncontrolling interest
9

 
—

 
9

 
18

 
—

 
18

 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings Attributable to BMS used for Diluted EPS Calculation
$
373

 
$
1,273

 
$
1,646

 
$
1,859

 
$
1,334

 
$
3,193

 
 
 
 
 
 
 
 
 
 
 
 
Average Common Shares Outstanding - Diluted
1,636

 
1,636

 
1,636

 
1,638

 
1,638

 
1,638

Diluted Earnings Per Share
$
0.23

 
$
0.78

 
$
1.01

 
$
1.13

 
$
0.82

 
$
1.95

 
 
 
 
 
 
 
 
 
 
 
 
Effective Tax Rate
26.1
%
 
(8.6
)%
 
17.5
%
 
18.2
%
 
(0.9
)%
 
17.3
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended June 30, 2017
 
Six Months Ended June 30, 2017
 
GAAP
 
Specified
Items(a)
 
Non-
GAAP
 
GAAP
 
Specified
Items(a)
 
Non-
GAAP
Gross Profit
$
3,575

 
$
130

 
$
3,705

 
$
7,239

 
$
130

 
$
7,369

Marketing, selling and administrative
1,187

 
—

 
1,187

 
2,272

 
—

 
2,272

Research and development
1,679

 
(489
)
 
1,190

 
2,982

 
(686
)
 
2,296

Other income (net)
(586
)
 
337

 
(249
)
 
(1,265
)
 
721

 
(544
)
Earnings Before Income Taxes
1,295

 
282

 
1,577

 
3,250

 
95

 
3,345

Provision for Income Taxes
373

 
20

 
353

 
802

 
92

 
710

Noncontrolling interest
6

 
—

 
6

 
(42
)
 
(59
)
 
17

 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings Attributable to BMS used for Diluted EPS Calculation
$
916

 
$
302

 
$
1,218

 
$
2,490

 
$
128

 
$
2,618

 
 
 
 
 
 
 
 
 
 
 
 
Average Common Shares Outstanding - Diluted
1,650

 
1,650

 
1,650

 
1,660

 
1,660

 
1,660

Diluted Earnings Per Share
$
0.56

 
$
0.18

 
$
0.74

 
$
1.50

 
$
0.08

 
$
1.58

 
 
 
 
 
 
 
 
 
 
 
 
Effective Tax Rate
28.8
%
 
(6.4
)%
 
22.4
%
 
24.7
%
 
(3.5
)%
 
21.2
%
(a)
Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.


12



BRISTOL-MYERS SQUIBB COMPANY
NET CASH/(DEBT) CALCULATION
AS OF JUNE 30, 2018 AND MARCH 31, 2018
(Unaudited, dollars in millions)
 
 
 
June 30, 2018
 
March 31, 2018
Cash and cash equivalents
 
$
4,999

 
$
5,342

Marketable securities - current
 
1,076

 
1,428

Marketable securities - non-current
 
2,117

 
2,252

     Cash, cash equivalents and marketable securities
 
8,192

 
9,022

Short-term debt obligations
 
(1,716
)
 
(1,925
)
Long-term debt
 
(5,671
)
 
(5,775
)
     Net cash position
 
$
805

 
$
1,322



13

 EX-99.2 3 q22018ex992.htm CERTAIN SUPPLEMENTAL INFORMATION Exhibit

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY
QUARTERLY TREND ANALYSIS OF REVENUES
(Unaudited, dollars in millions)
Revenues
 
2017
 
2018
 
% Change
 
FX Impact
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
    United States
 
$
2,738

 
$
2,865

 
$
5,603

 
$
2,864

 
$
8,467

 
$
2,891

 
$
11,358

 
$
2,778

 
$
3,230

 
$
6,008

 
 
 
 
 
 
 
 
 
13
 %
 
7
 %
 
—

 
—

    Europe
 
1,146

 
1,188

 
2,334

 
1,262

 
3,596

 
1,392

 
4,988

 
1,406

 
1,408

 
2,814

 
 
 
 
 
 
 
 
 
19
 %
 
21
 %
 
9
%
 
12
%
    Rest of the World
 
925

 
963

 
1,888

 
970

 
2,858

 
1,019

 
3,877

 
873

 
923

 
1,796

 
 
 
 
 
 
 
 
 
(4
)%
 
(5
)%
 
1
%
 
2
%
    Other
 
120

 
128

 
248

 
158

 
406

 
147

 
553

 
136

 
143

 
279

 
 
 
 
 
 
 
 
 
12
 %
 
13
 %
 
N/A

 
N/A

Total
 
$
4,929

 
$
5,144

 
$
10,073

 
$
5,254

 
$
15,327

 
$
5,449

 
$
20,776

 
$
5,193

 
$
5,704

 
$
10,897

 
 
 
 
 
 
 
 
 
11
 %
 
8
 %
 
2
%
 
3
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% of Revenues
 
2017
 
2018
 
 
 
 
 
 
 
 
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
 
 
 
 
 
 
 
    United States
 
55.5
%
 
55.7
%
 
55.6
%
 
54.5
%
 
55.2
%
 
53.1
%
 
54.7
%
 
53.5
%
 
56.6
%
 
55.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Europe
 
23.3
%
 
23.1
%
 
23.2
%
 
24.0
%
 
23.5
%
 
25.5
%
 
24.0
%
 
27.1
%
 
24.7
%
 
25.8
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Rest of the World
 
18.8
%
 
18.7
%
 
18.7
%
 
18.5
%
 
18.6
%
 
18.7
%
 
18.7
%
 
16.8
%
 
16.2
%
 
16.5
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Other
 
2.4
%
 
2.5
%
 
2.5
%
 
3.0
%
 
2.7
%
 
2.7
%
 
2.6
%
 
2.6
%
 
2.5
%
 
2.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


1

BRISTOL-MYERS SQUIBB COMPANY
EARNINGS FROM OPERATIONS
(Unaudited, dollars and shares in millions except per share data)
 
 
2017
 
2018
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Net product sales
 
$
4,580

 
$
4,770

 
$
9,350

 
$
4,862

 
$
14,212

 
$
5,046

 
$
19,258

 
$
4,972

 
$
5,461

 
$
10,433

 
 
 
 
 
 
 
 
 
14
 %
 
12
 %
Alliance and other revenues
 
349

 
374

 
723

 
392

 
1,115

 
403

 
1,518

 
221

 
243

 
464

 
 
 
 
 
 
 
 
 
(35
)%
 
(36
)%
Total Revenues
 
$
4,929

 
$
5,144

 
$
10,073

 
$
5,254

 
$
15,327

 
$
5,449

 
$
20,776

 
$
5,193

 
$
5,704

 
$
10,897

 
 
 
 
 
 
 
 
 
11
 %
 
8
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of products sold
 
1,265

 
1,569

 
2,834

 
1,579

 
4,413

 
1,681

 
6,094

 
1,584

 
1,625

 
3,209

 
 
 
 
 
 
 
 
 
4
 %
 
13
 %
Marketing, selling and administrative
 
1,085

 
1,187

 
2,272

 
1,163

 
3,435

 
1,316

 
4,751

 
980

 
1,131

 
2,111

 
 
 
 
 
 
 
 
 
(5
)%
 
(7
)%
Research and development
 
1,303

 
1,679

 
2,982

 
1,561

 
4,543

 
1,939

 
6,482

 
1,250

 
2,435

 
3,685

 
 
 
 
 
 
 
 
 
45
 %
 
24
 %
Other income (net)
 
(679
)
 
(586
)
 
(1,265
)
 
(232
)
 
(1,497
)
 
(185
)
 
(1,682
)
 
(400
)
 
(4
)
 
(404
)
 
 
 
 
 
 
 
 
 
(99
)%
 
(68
)%
Total Expenses
 
2,974

 
3,849

 
6,823

 
4,071

 
10,894

 
4,751

 
15,645

 
3,414

 
5,187

 
8,601

 
 
 
 
 
 
 
 
 
35
 %
 
26
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings Before Income Taxes
 
$
1,955

 
$
1,295

 
$
3,250

 
$
1,183

 
$
4,433

 
$
698

 
$
5,131

 
$
1,779

 
$
517

 
$
2,296

 
 
 
 
 
 
 
 
 
(60
)%
 
(29
)%
Provision for Income Taxes
 
429

 
373

 
802

 
327

 
1,129

 
3,027

 
4,156

 
284

 
135

 
419

 
 
 
 
 
 
 
 
 
(64
)%
 
(48
)%
Net Earnings/(Loss)
 
$
1,526

 
$
922

 
$
2,448

 
$
856

 
$
3,304

 
$
(2,329
)
 
$
975

 
$
1,495

 
$
382

 
$
1,877

 
 
 
 
 
 
 
 
 
(59
)%
 
(23
)%
Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
(48
)
 
6

 
(42
)
 
11

 
(31
)
 
(1
)
 
(32
)
 
9

 
9

 
18

 
 
 
 
 
 
 
 
 
50
 %
 
**

Net Earnings/(Loss) Attributable to BMS
 
$
1,574

 
$
916

 
$
2,490

 
$
845

 
$
3,335

 
$
(2,328
)
 
$
1,007

 
$
1,486

 
$
373

 
$
1,859

 
 
 
 
 
 
 
 
 
(59
)%
 
(25
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Earnings/(Loss) per Common Share*
 
$
0.94

 
$
0.56

 
$
1.50

 
$
0.51

 
$
2.02

 
$
(1.42
)
 
$
0.61

 
$
0.91

 
$
0.23

 
$
1.13

 
 
 
 
 
 
 
 
 
(59
)%
 
(25
)%
Average Common Shares Outstanding - Diluted
 
1,671

 
1,650

 
1,660

 
1,645

 
1,655

 
1,635

 
1,652

 
1,640

 
1,636

 
1,638

 
 
 
 
 
 
 
 
 
(1
)%
 
(1
)%
Dividends declared per common share
 
$
0.39

 
$
0.39

 
$
0.78

 
$
0.39

 
$
1.17

 
$
0.40

 
$
1.57

 
$
0.40

 
$
0.40

 
$
0.80

 
 
 
 
 
 
 
 
 
3
 %
 
3
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2017
 
2018
 
 
 
 
% of Total Revenues
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
 
 
 
Gross Margin
 
74.3
%
 
69.5
%
 
71.9
%
 
69.9
%
 
71.2
%
 
69.2
%
 
70.7
%
 
69.5
%
 
71.5
%
 
70.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Ratios
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
 
21.9
%
 
28.8
%
 
24.7
%
 
27.6
%
 
25.5
%
 
433.7
%
 
81.0
%
 
16.0
%
 
26.1
%
 
18.2
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other income (net)
 
2017
 
2018
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Interest expense
 
$
45

 
$
52

 
$
97

 
$
48

 
$
145

 
$
51

 
$
196

 
$
46

 
$
45

 
$
91

 
 
 
 
 
 
 
 
 
(13
)%
 
(6
)%
Investment income
 
(26
)
 
(29
)
 
(55
)
 
(32
)
 
(87
)
 
(39
)
 
(126
)
 
(36
)
 
(38
)
 
(74
)
 
 
 
 
 
 
 
 
 
31
 %
 
35
 %
Loss/(gain) on equity investments
 
(7
)
 
(5
)
 
(12
)
 
(5
)
 
(17
)
 
(11
)
 
(28
)
 
(15
)
 
356

 
341

 
 
 
 
 
 
 
 
 
**

 
**

Provision for restructuring
 
164

 
15

 
179

 
28

 
207

 
86

 
293

 
20

 
37

 
57

 
 
 
 
 
 
 
 
 
**

 
(68
)%
Litigation and other settlements
 
(484
)
 
(5
)
 
(489
)
 
—

 
(489
)
 
2

 
(487
)
 
—

 
(1
)
 
(1
)
 
 
 
 
 
 
 
 
 
(80
)%
 
(100
)%
Equity in net income of affiliates
 
(18
)
 
(20
)
 
(38
)
 
(21
)
 
(59
)
 
(16
)
 
(75
)
 
(24
)
 
(27
)
 
(51
)
 
 
 
 
 
 
 
 
 
35
 %
 
34
 %
Divestiture (gains)/losses
 
(127
)
 
—

 
(127
)
 
1

 
(126
)
 
(38
)
 
(164
)
 
(45
)
 
(25
)
 
(70
)
 
 
 
 
 
 
 
 
 
N/A

 
(45
)%
Royalties and licensing income
 
(199
)
 
(685
)
 
(884
)
 
(209
)
 
(1,093
)
 
(258
)
 
(1,351
)
 
(367
)
 
(353
)
 
(720
)
 
 
 
 
 
 
 
 
 
(48
)%
 
(19
)%
Transition and other service fees
 
(7
)
 
(13
)
 
(20
)
 
(12
)
 
(32
)
 
(5
)
 
(37
)
 
(4
)
 
(1
)
 
(5
)
 
 
 
 
 
 
 
 
 
(92
)%
 
(75
)%
Pension and postretirement
 
1

 
(11
)
 
(10
)
 
(19
)
 
(29
)
 
28

 
(1
)
 
(11
)
 
(19
)
 
(30
)
 
 
 
 
 
 
 
 
 
73

 
**

Intangible asset impairment
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
64

 
—

 
64

 
 
 
 
 
 
 
 
 
—

 
N/A

Equity investment impairment
 
—

 
—

 
—

 
—

 
—

 
5

 
5

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
—

 
—

Loss on debt redemption
 
—

 
109

 
109

 
—

 
109

 
—

 
109

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
(100
)%
 
(100
)%
Other
 
(21
)
 
6

 
(15
)
 
(11
)
 
(26
)
 
10

 
(16
)
 
(28
)
 
22

 
(6
)
 
 
 
 
 
 
 
 
 
**

 
(60
)%
 
 
$
(679
)
 
$
(586
)
 
$
(1,265
)
 
$
(232
)
 
$
(1,497
)
 
$
(185
)
 
$
(1,682
)
 
$
(400
)
 
$
(4
)
 
$
(404
)
 
 
 
 
 
 
 
 
 
(99
)%
 
(68
)%
*
Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.
**
In excess of +/- 100%


2

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT
FOR THE PERIOD ENDED JUNE 30, 2018
(Unaudited, dollars in millions)
QUARTER-TO-DATE
 
2018
 
2017
 
Growth $
 
Growth %
 
Favorable /
(Unfavorable)
FX Impact $ *
 
2018
Excluding FX
 
Favorable /
(Unfavorable)
FX Impact % *
 
Growth %
Excluding FX
Revenues
 
$
5,704

 
$
5,144

 
$
560

 
11
 %
 
$
107

 
$
5,597

 
2
 %
 
9
 %
Gross profit
 
4,079

 
3,575

 
504

 
14
 %
 
N/A

 
N/A

 
N/A

 
N/A

Gross profit excluding specified items (a)
 
4,093

 
3,705

 
388

 
10
 %
 
N/A

 
N/A

 
N/A

 
N/A

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gross profit excluding specified items as a % of revenues
 
71.8
%
 
72.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
1,131

 
1,187

 
(56
)
 
(5
)%
 
(20
)
 
1,111

 
(1
)%
 
(6
)%
Marketing, selling and administrative excluding specified items (a)
 
1,131

 
1,187

 
(56
)
 
(5
)%
 
(20
)
 
1,111

 
(1
)%
 
(6
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative excluding specified items as a % of revenues
 
19.8
%
 
23.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
2,435

 
1,679

 
756

 
45
 %
 
(9
)
 
2,426

 
(1
)%
 
44
 %
Research and development excluding specified items (a)
 
1,341

 
1,190

 
151

 
13
 %
 
(9
)
 
1,332

 
(1
)%
 
12
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development excluding specified items as a % of revenues
 
23.5
%
 
23.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YEAR-TO-DATE
 
2018
 
2017
 
Growth $
 
Growth %
 
Favorable /
(Unfavorable)
FX Impact $ *
 
2018 Excluding FX
 
Favorable /
(Unfavorable)
FX Impact % *
 
Growth %
Excluding FX
Revenues
 
$
10,897

 
$
10,073

 
$
824

 
8
 %
 
$
308

 
$
10,589

 
3
 %
 
5
 %
Gross profit
 
7,688

 
7,239

 
449

 
6
 %
 
N/A

 
N/A

 
N/A

 
N/A

Gross profit excluding specified items (a)
 
7,715

 
7,369

 
346

 
5
 %
 
N/A

 
N/A

 
N/A

 
N/A

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Gross profit excluding specified items as a % of revenues
 
70.8
%
 
73.2
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
2,111

 
2,272

 
(161
)
 
(7
)%
 
(55
)
 
2,056

 
(3
)%
 
(10
)%
Marketing, selling and administrative excluding specified items (a)
 
2,110

 
2,272

 
(162
)
 
(7
)%
 
(55
)
 
2,055

 
(3
)%
 
(10
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative excluding specified items as a % of revenues
 
19.4
%
 
22.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
3,685

 
2,982

 
703

 
24
 %
 
(31
)
 
3,654

 
(1
)%
 
23
 %
Research and development excluding specified items (a)
 
2,511

 
2,296

 
215

 
9
 %
 
(25
)
 
2,486

 
(1
)%
 
8
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development excluding specified items as a % of revenues
 
23.0
%
 
22.8
%
 
 
 
 
 
 
 
 
 
 
 
 
(a)
Refer to the Specified Items schedule for further details.
*
Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales and expenses.

3

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2017
 
2018
 
Growth $
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
1,127

 
$
1,195

 
$
2,322

 
$
1,265

 
$
3,587

 
$
1,361

 
$
4,948

 
$
1,511

 
$
1,627

 
$
3,138

 
 
 
 
 
 
 
 
 
$
432

 
$
816

 
36
 %
 
35
 %
Eliquis
 
1,101

 
1,176

 
2,277

 
1,232

 
3,509

 
1,363

 
4,872

 
1,506

 
1,650

 
3,156

 
 
 
 
 
 
 
 
 
474

 
879

 
40
 %
 
39
 %
Orencia
 
535

 
650

 
1,185

 
632

 
1,817

 
662

 
2,479

 
593

 
711

 
1,304

 
 
 
 
 
 
 
 
 
61

 
119

 
9
 %
 
10
 %
Sprycel
 
463

 
506

 
969

 
509

 
1,478

 
527

 
2,005

 
438

 
535

 
973

 
 
 
 
 
 
 
 
 
29

 
4

 
6
 %
 
—

Yervoy
 
330

 
322

 
652

 
323

 
975

 
269

 
1,244

 
249

 
315

 
564

 
 
 
 
 
 
 
 
 
(7
)
 
(88
)
 
(2
)%
 
(13
)%
Empliciti
 
53

 
55

 
108

 
60

 
168

 
63

 
231

 
55

 
64

 
119

 
 
 
 
 
 
 
 
 
9

 
11

 
16
 %
 
10
 %
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
282

 
273

 
555

 
264

 
819

 
233

 
1,052

 
225

 
179

 
404

 
 
 
 
 
 
 
 
 
(94
)
 
(151
)
 
(34
)%
 
(27
)%
Sustiva Franchise(a)
 
184

 
188

 
372

 
183

 
555

 
174

 
729

 
84

 
73

 
157

 
 
 
 
 
 
 
 
 
(115
)
 
(215
)
 
(61
)%
 
(58
)%
Reyataz Franchise
 
193

 
188

 
381

 
174

 
555

 
143

 
698

 
124

 
117

 
241

 
 
 
 
 
 
 
 
 
(71
)
 
(140
)
 
(38
)%
 
(37
)%
Hepatitis C Franchise(b)
 
162

 
112

 
274

 
73

 
347

 
59

 
406

 
3

 
12

 
15

 
 
 
 
 
 
 
 
 
(100
)
 
(259
)
 
(89
)%
 
(95
)%
Other Brands
 
499

 
479

 
978

 
539

 
1,517

 
595

 
2,112

 
405

 
421

 
826

 
 
 
 
 
 
 
 
 
(58
)
 
(152
)
 
(12
)%
 
(16
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
$
4,929

 
$
5,144

 
$
10,073

 
$
5,254

 
$
15,327

 
$
5,449

 
$
20,776

 
$
5,193

 
$
5,704

 
$
10,897

 
 
 
 
 
 
 
 
 
$
560

 
$
824

 
11
 %
 
8
 %
(a)
The Sustiva Franchise includes sales of Sustiva, BMS's share of Atripla revenues in Europe, and U.S. Atripla royalty revenue beginning January 1, 2018.
(b)
Includes Daklinza (daclatasvir) and Sunvepra (asunaprevir) revenues.

4

BRISTOL-MYERS SQUIBB COMPANY
U.S. REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2017
 
2018
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
761

 
$
768

 
$
1,529

 
$
778

 
$
2,307

 
$
795

 
$
3,102

 
$
938

 
$
1,024

 
$
1,962

 
 
 
 
 
 
 
 
 
33
 %
 
28
 %
Eliquis
 
699

 
703

 
1,402

 
717

 
2,119

 
768

 
2,887

 
885

 
979

 
1,864

 
 
 
 
 
 
 
 
 
39
 %
 
33
 %
Orencia(a)
 
362

 
449

 
811

 
432

 
1,243

 
461

 
1,704

 
385

 
501

 
886

 
 
 
 
 
 
 
 
 
12
 %
 
9
 %
Sprycel
 
247

 
281

 
528

 
278

 
806

 
299

 
1,105

 
214

 
310

 
524

 
 
 
 
 
 
 
 
 
10
 %
 
(1
)%
Yervoy
 
243

 
245

 
488

 
239

 
727

 
181

 
908

 
162

 
228

 
390

 
 
 
 
 
 
 
 
 
(7
)%
 
(20
)%
Empliciti
 
36

 
37

 
73

 
39

 
112

 
39

 
151

 
37

 
41

 
78

 
 
 
 
 
 
 
 
 
11
 %
 
7
 %
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
14

 
12

 
26

 
14

 
40

 
13

 
53

 
10

 
9

 
19

 
 
 
 
 
 
 
 
 
(25
)%
 
(27
)%
Sustiva Franchise(b)
 
153

 
161

 
314

 
157

 
471

 
151

 
622

 
10

 
8

 
18

 
 
 
 
 
 
 
 
 
(95
)%
 
(94
)%
Reyataz Franchise
 
88

 
87

 
175

 
85

 
260

 
67

 
327

 
51

 
54

 
105

 
 
 
 
 
 
 
 
 
(38
)%
 
(40
)%
Hepatitis C Franchise(c)
 
42

 
30

 
72

 
24

 
96

 
13

 
109

 
5

 
(2
)
 
3

 
 
 
 
 
 
 
 
 
**

 
(96
)%
Other Brands
 
93

 
92

 
185

 
101

 
286

 
104

 
390

 
81

 
78

 
159

 
 
 
 
 
 
 
 
 
(15
)%
 
(14
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total(d)
 
$
2,738

 
$
2,865

 
$
5,603

 
$
2,864

 
$
8,467

 
$
2,891

 
$
11,358

 
$
2,778

 
$
3,230

 
$
6,008

 
 
 
 
 
 
 
 
 
13
 %
 
7
 %
**
 In excess of +/- 100%
(a)
In 2018, U.S. Sustiva Franchise revenues include sales of Sustiva only.
(b)
Includes revenues of Daklinza (daclastasvir) only.
(c)
Includes United States and Puerto Rico.


5

BRISTOL-MYERS SQUIBB COMPANY
INTERNATIONAL REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2017
 
2018
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
366

 
$
427

 
$
793

 
$
487

 
$
1,280

 
$
566

 
$
1,846

 
$
573

 
$
603

 
$
1,176

 
 
 
 
 
 
 
 
 
41
 %
 
48
 %
Eliquis
 
402

 
473

 
875

 
515

 
1,390

 
595

 
1,985

 
621

 
671

 
1,292

 
 
 
 
 
 
 
 
 
42
 %
 
48
 %
Orencia
 
173

 
201

 
374

 
200

 
574

 
201

 
775

 
208

 
210

 
418

 
 
 
 
 
 
 
 
 
4
 %
 
12
 %
Sprycel
 
216

 
225

 
441

 
231

 
672

 
228

 
900

 
224

 
225

 
449

 
 
 
 
 
 
 
 
 
—

 
2
 %
Yervoy
 
87

 
77

 
164

 
84

 
248

 
88

 
336

 
87

 
87

 
174

 
 
 
 
 
 
 
 
 
13
 %
 
6
 %
Empliciti
 
17

 
18

 
35

 
21

 
56

 
24

 
80

 
18

 
23

 
41

 
 
 
 
 
 
 
 
 
28
 %
 
17
 %
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baraclude
 
268

 
261

 
529

 
250

 
779

 
220

 
999

 
215

 
170

 
385

 
 
 
 
 
 
 
 
 
(35
)%
 
(27
)%
Sustiva Franchise(a)
 
31

 
27

 
58

 
26

 
84

 
23

 
107

 
74

 
65

 
139

 
 
 
 
 
 
 
 
 
**

 
**

Reyataz Franchise
 
105

 
101

 
206

 
89

 
295

 
76

 
371

 
73

 
63

 
136

 
 
 
 
 
 
 
 
 
(38
)%
 
(34
)%
Hepatitis C Franchise(b)
 
120

 
82

 
202

 
49

 
251

 
46

 
297

 
(2
)
 
14

 
12

 
 
 
 
 
 
 
 
 
(83
)%
 
(94
)%
Other Brands
 
406

 
387

 
793

 
438

 
1,231

 
491

 
1,722

 
324

 
343

 
667

 
 
 
 
 
 
 
 
 
(11
)%
 
(16
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total(c)
 
$
2,191

 
$
2,279

 
$
4,470

 
$
2,390

 
$
6,860

 
$
2,558

 
$
9,418

 
$
2,415

 
$
2,474

 
$
4,889

 
 
 
 
 
 
 
 
 
9
 %
 
9
 %

**
In excess of +/- 100%
(a)
The Sustiva Franchise includes BMS's share of Atripla revenues in Europe, and U.S. Atripla royalty revenue beginning January 1, 2018.
(b)
Includes Daklinza (daclatasvir) and Sunvepra (asunaprevir) revenues.
(c)
When adjusted for foreign exchange impact, total revenues increased 4% for the second quarter.



6

BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
(Unaudited, dollars in millions)
 
 
2017
 
2018
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Impairment charges
 
$
—

 
$
127

 
$
127

 
$
1

 
$
128

 
$
18

 
$
146

 
$
10

 
$
—

 
$
10

 
 
 
 
 
 
 
 
Accelerated depreciation and other shutdown costs
 
—

 
3

 
3

 
—

 
3

 
—

 
3

 
3

 
14

 
17

 
 
 
 
 
 
 
 
Cost of products sold
 
—

 
130

 
130

 
1

 
131

 
18

 
149

 
13

 
14

 
27

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
—

 
—

 
—

 
—

 
—

 
1

 
1

 
1

 
—

 
1

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
License and asset acquisition charges
 
50

 
393

 
443

 
310

 
753

 
377

 
1,130

 
60

 
1,075

 
1,135

 
 
 
 
 
 
 
 
IPRD impairments
 
75

 
—

 
75

 
—

 
75

 
—

 
75

 
—

 
—

 
—

 
 
 
 
 
 
 
 
Site exit costs and other
 
72

 
96

 
168

 
64

 
232

 
151

 
383

 
20

 
19

 
39

 
 
 
 
 
 
 
 
Research and development
 
197

 
489

 
686

 
374

 
1,060

 
528

 
1,588

 
80

 
1,094

 
1,174

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loss/(gain) on equity investments
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(15
)
 
356

 
341

 
 
 
 
 
 
 
 
Provision for restructuring
 
164

 
15

 
179

 
28

 
207

 
86

 
293

 
20

 
37

 
57

 
 
 
 
 
 
 
 
Litigation and other settlements
 
(481
)
 
—

 
(481
)
 
—

 
(481
)
 
—

 
(481
)
 
—

 
—

 
—

 
 
 
 
 
 
 
 
Divestiture gains
 
(100
)
 
—

 
(100
)
 
—

 
(100
)
 
(26
)
 
(126
)
 
(43
)
 
(25
)
 
(68
)
 
 
 
 
 
 
 
 
Royalties and licensing income
 
—

 
(497
)
 
(497
)
 
—

 
(497
)
 
—

 
(497
)
 
(50
)
 
(25
)
 
(75
)
 
 
 
 
 
 
 
 
Pension and postretirement
 
33

 
36

 
69

 
22

 
91

 
71

 
162

 
31

 
37

 
68

 
 
 
 
 
 
 
 
Intangible asset impairment
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
64

 
—

 
64

 
 
 
 
 
 
 
 
Loss on debt redemption
 
—

 
109

 
109

 
—

 
109

 
—

 
109

 
—

 
—

 
—

 
 
 
 
 
 
 
 
Other income (net)
 
(384
)
 
(337
)
 
(721
)
 
50

 
(671
)
 
131

 
(540
)
 
7

 
380

 
387

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to pretax income
 
(187
)
 
282

 
95

 
425

 
520

 
678

 
1,198

 
101

 
1,488

 
1,589

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Income taxes on specified items
 
72

 
20

 
92

 
(41
)
 
51

 
(138
)
 
(87
)
 
(8
)
 
(218
)
 
(226
)
 
 
 
 
 
 
 
 
Income taxes attributed to U.S. tax reform
 
—

 
—

 
—

 
—

 
—

 
2,911

 
2,911

 
(32
)
 
3

 
(29
)
 
 
 
 
 
 
 
 
Income taxes
 
72

 
20

 
92

 
(41
)
 
51

 
2,773

 
2,824

 
(40
)
 
(215
)
 
(255
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to net earnings
 
(115
)
 
302

 
187

 
384

 
571

 
3,451

 
4,022

 
61

 
1,273

 
1,334

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncontrolling interest
 
(59
)
 
—

 
(59
)
 
—

 
(59
)
 
—

 
(59
)
 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to net earnings used for diluted Non-GAAP EPS calculation
 
$
(174
)
 
$
302

 
$
128

 
$
384

 
$
512

 
$
3,451

 
$
3,963

 
$
61

 
$
1,273

 
$
1,334

 
 
 
 
 
 
 
 



7

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
(Unaudited, dollars in millions)
 
 
2017
 
2018
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Gross Profit
 
$
3,664

 
$
3,575

 
$
7,239

 
$
3,675

 
$
10,914

 
$
3,768

 
$
14,682

 
$
3,609

 
$
4,079

 
$
7,688

 
 
 
 
 
 
 
 
Specified items (a)
 
—

 
130

 
130

 
1

 
131

 
18

 
149

 
13

 
14

 
27

 
 
 
 
 
 
 
 
Gross profit excluding specified items
 
3,664

 
3,705

 
7,369

 
3,676

 
11,045

 
3,786

 
14,831

 
3,622

 
4,093

 
7,715

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative
 
1,085

 
1,187

 
2,272

 
1,163

 
3,435

 
1,316

 
4,751

 
980

 
1,131

 
2,111

 
 
 
 
 
 
 
 
Specified items (a)
 
—

 
—

 
—

 
—

 
—

 
(1
)
 
(1
)
 
(1
)
 
—

 
(1
)
 
 
 
 
 
 
 
 
Marketing, selling and administrative excluding specified items
 
1,085

 
1,187

 
2,272

 
1,163

 
3,435

 
1,315

 
4,750

 
979

 
1,131

 
2,110

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
1,303

 
1,679

 
2,982

 
1,561

 
4,543

 
1,939

 
6,482

 
1,250

 
2,435

 
3,685

 
 
 
 
 
 
 
 
Specified items (a)
 
(197
)
 
(489
)
 
(686
)
 
(374
)
 
(1,060
)
 
(528
)
 
(1,588
)
 
(80
)
 
(1,094
)
 
(1,174
)
 
 
 
 
 
 
 
 
Research and development excluding specified items
 
1,106

 
1,190

 
2,296

 
1,187

 
3,483

 
1,411

 
4,894

 
1,170

 
1,341

 
2,511

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other income (net)
 
(679
)
 
(586
)
 
(1,265
)
 
(232
)
 
(1,497
)
 
(185
)
 
(1,682
)
 
(400
)
 
(4
)
 
(404
)
 
 
 
 
 
 
 
 
Specified items (a)
 
384

 
337

 
721

 
(50
)
 
671

 
(131
)
 
540

 
(7
)
 
(380
)
 
(387
)
 
 
 
 
 
 
 
 
Other income (net) excluding specified items
 
(295
)
 
(249
)
 
(544
)
 
(282
)
 
(826
)
 
(316
)
 
(1,142
)
 
(407
)
 
(384
)
 
(791
)
 
 
 
 
 
 
 
 

(a)
Refer to the Specified Items schedule for further details.


8

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF GAAP TO NON-GAAP EPS
(Unaudited, dollars in millions)
 
 
2017
 
2018
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Earnings before income taxes
 
$
1,955

 
$
1,295

 
$
3,250

 
$
1,183

 
$
4,433

 
$
698

 
$
5,131

 
$
1,779

 
$
517

 
$
2,296

 
 
 
 
 
 
 
 
Specified items(a)
 
(187
)
 
282

 
95

 
425

 
520

 
678

 
1,198

 
101

 
1,488

 
1,589

 
 
 
 
 
 
 
 
Earnings before income taxes excluding specified items
 
1,768

 
1,577

 
3,345

 
1,608

 
4,953

 
1,376

 
6,329

 
1,880

 
2,005

 
3,885

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provision for income taxes
 
429

 
373

 
802

 
327

 
1,129

 
3,027

 
4,156

 
284

 
135

 
419

 
 
 
 
 
 
 
 
Tax on specified items(a)
 
72

 
20

 
92

 
(41
)
 
51

 
(138
)
 
(87
)
 
(8
)
 
(218
)
 
(226
)
 
 
 
 
 
 
 
 
Income taxes attributed to U.S. tax reform(a)
 
—

 
—

 
—

 
—

 
—

 
2,911

 
2,911

 
(32
)
 
3

 
(29
)
 
 
 
 
 
 
 
 
Provision for income taxes excluding tax on specified items and income taxes attributed to U.S. tax reform
 
357

 
353

 
710

 
368

 
1,078

 
254

 
1,332

 
324

 
350

 
674

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
(48
)
 
6

 
(42
)
 
11

 
(31
)
 
(1
)
 
(32
)
 
9

 
9

 
18

 
 
 
 
 
 
 
 
Specified items(a)
 
(59
)
 
—

 
(59
)
 
—

 
(59
)
 
—

 
(59
)
 
—

 
—

 
—

 
 
 
 
 
 
 
 
Net Earnings/(Loss) Attributable to Noncontrolling Interest excluding specified items
 
11

 
6

 
17

 
11

 
28

 
(1
)
 
27

 
9

 
9

 
18

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings/(Loss) Attributable to BMS used for Diluted EPS Calculation - GAAP
 
1,574

 
916

 
2,490

 
845

 
3,335

 
(2,328
)
 
1,007

 
1,486

 
373

 
1,859

 
 
 
 
 
 
 
 
Specified items(a)
 
(174
)
 
302

 
128

 
384

 
512

 
3,451

 
3,963

 
61

 
1,273

 
1,334

 
 
 
 
 
 
 
 
Net Earnings Attributable to BMS used for Diluted EPS Calculation excluding specified items - Non-GAAP
 
1,400

 
1,218

 
2,618

 
1,229

 
3,847

 
1,123

 
4,970

 
1,547

 
1,646

 
3,193

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average Common Shares Outstanding - Diluted- GAAP
 
1,671

 
1,650

 
1,660

 
1,645

 
1,655

 
1,635

 
1,652

 
1,640

 
1,636

 
1,638

 
 
 
 
 
 
 
 
Weighted-average Common Shares Outstanding - Diluted- Non-GAAP
 
1,671

 
1,650

 
1,660

 
1,645

 
1,655

 
1,642

 
1,652

 
1,640

 
1,636

 
1,638

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Earnings/(Loss) Per Share - GAAP
 
$
0.94

 
$
0.56

 
$
1.50

 
$
0.51

 
$
2.02

 
$
(1.42
)
 
$
0.61

 
$
0.91

 
$
0.23

 
$
1.13

 
 
 
 
 
 
 
 
Diluted Earnings/(Loss) Per Share Attributable to Specified Items
 
(0.10
)
 
0.18

 
0.08

 
0.24

 
0.30

 
2.10

 
2.40

 
0.03

 
0.78

 
0.82

 
 
 
 
 
 
 
 
Diluted Earnings Per Share - Non-GAAP
 
$
0.84

 
$
0.74

 
$
1.58

 
$
0.75

 
$
2.32

 
$
0.68

 
$
3.01

 
$
0.94

 
$
1.01

 
$
1.95

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective Tax Rate
 
21.9
 %
 
28.8
 %
 
24.7
 %
 
27.6
 %
 
25.5
 %
 
433.7
 %
 
81.0
 %
 
16.0
%
 
26.1
 %
 
18.2
 %
 
 
 
 
 
 
 
 
Specified items (a)
 
(1.7
)%
 
(6.4
)%
 
(3.5
)%
 
(4.7
)%
 
(3.7
)%
 
(415.2
)%
 
(60.0
)%
 
1.2
%
 
(8.6
)%
 
(0.9
)%
 
 
 
 
 
 
 
 
Effective Tax Rate excluding specified items
 
20.2
 %
 
22.4
 %
 
21.2
 %
 
22.9
 %
 
21.8
 %
 
18.5
 %
 
21.0
 %
 
17.2
%
 
17.5
 %
 
17.3
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)
Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

9

BRISTOL-MYERS SQUIBB COMPANY
SELECTED BALANCE SHEET INFORMATION
(Unaudited, dollars in millions)
 
 
 
March 31,
2017
 
June 30,
2017
 
September 30,
2017
 
December 31,
2017
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31,
2018
Cash and cash equivalents
 
$
3,910

 
$
3,470

 
$
4,644

 
$
5,421

 
$
5,342

 
$
4,999

 
 
 
 
Marketable securities - current
 
2,199

 
3,035

 
2,478

 
1,391

 
1,428

 
1,076

 
 
 
 
Marketable securities - non-current
 
2,685

 
2,580

 
2,526

 
2,480

 
2,252

 
2,117

 
 
 
 
     Cash, cash equivalents and marketable securities
 
8,794

 
9,085

 
9,648

 
9,292

 
9,022

 
8,192

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short-term debt obligations
 
(1,197
)
 
(1,306
)
 
(1,461
)
 
(987
)
 
(1,925
)
 
(1,716
)
 
 
 
 
Long-term debt
 
(7,237
)
 
(6,911
)
 
(6,982
)
 
(6,975
)
 
(5,775
)
 
(5,671
)
 
 
 
 
     Net cash position
 
$
360

 
$
868

 
$
1,205

 
$
1,330

 
$
1,322

 
$
805

 
 
 
 


10

BRISTOL-MYERS SQUIBB COMPANY
2018 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS
EXCLUDING PROJECTED SPECIFIED ITEMS
 
 
Full Year 2018
 
 
 
 
 
 
 
 
Pre-tax
 
Tax
 
After-tax
 
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP
 
 
 
 
$2.68 to $2.78

 
 
 
 
 
 
 
 
 
 
Projected Specified Items:
 
 
 
 
 
 
Restructuring, accelerated depreciation and other exit costs (1)
0.16

 
0.03

 
0.13

 
Divestiture gains and licensing income
(0.14
)
 
(0.04
)
 
(0.10
)
 
Research and development license and asset acquisition charges
0.69

 
0.14

 
0.55

 
Pension charges
0.08

 
0.02

 
0.06

 
Loss/(gain) on equity investments

0.21

 
(0.01
)
 
0.22

 
Other
0.04

 
0.03

 
0.01

 
Total
1.04

 
0.17

 
0.87

 
 
 
 
 
 
 
 
 
 
Projected Diluted Earnings Attributable to Shareholders per Common Share - Non-GAAP
 
 
 
 
$3.55 to $3.65

 
 
 
 
 
 
 
 
 
 
(1) Includes items recognized in Cost of products sold, Research and development and Other income (net).
 
 
 
 
 
The following table summarizes the company's 2018 financial guidance:
 
Line item
 
GAAP
 
Non-GAAP
 
Worldwide revenues
 
Increasing in the mid- to high-single digits
 
Increasing in the mid- to high-single digits
 
 
 
 
 
Gross margin as a percent of revenue
 
Approximately 70%
 
Approximately 70%
 
Marketing, selling and administrative expense
 
Decreasing in the low- to mid-single digit range
 
Decreasing in the low- to mid-single digit range
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development expense
 
Increasing in the low-single digits
 
Increasing in the high-single digits
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
 
Between 17%-18%
 
Between 17%-18%
The GAAP financial results for the full year 2018 will include specified items, including charges associated with restructuring, downsizing and streamlining worldwide operations, gains/losses on divestitures and equity investments, license and asset acquisition charges, pension charges and other specified items that have not yet been identified and quantified, including litigation and other settlements, licensed asset impairments and finalization of the deemed repatriation tax, among other items. For a fuller discussion of items that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports Second Quarter 2018 Financial Results, July 26, 2018 including “2018 Financial Guidance” and “Use of non-GAAP Financial Information” therein.


11
 GRAPHIC 4 bmslogoq12018a01.jpg GRAPHIC begin 644 bmslogoq12018a01.jpg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end